<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92366">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01851954</url>
  </required_header>
  <id_info>
    <org_study_id>clarith_VLBW</org_study_id>
    <nct_id>NCT01851954</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Clarithromycin in Very Low Birth Weight (VLBW)</brief_title>
  <official_title>Pharmacokinetic Study of Clarithromycin in Premature Infants With Safety Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics of clarithromycin which is
      used for premature infants with ureaplasma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>72 hours after first infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC, Cmax</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Very Low Birth Weight Infant</condition>
  <condition>Ureaplasma/Mycoplasma Positive</condition>
  <arm_group>
    <arm_group_label>clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Population PK</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>IV clarithromycin infusion</description>
    <arm_group_label>clarithromycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  birthweight &lt; 1500gm

          -  transtracheal aspirate/gastric juice ; ureaplasma/mycoplasma(+)

        Exclusion Criteria:

          -  sepsis, hypotension, shock

          -  major congenital anomaly
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han-Suk Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Han Shin, MD</last_name>
    <email>revival421@empal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Han Shin, MD</last_name>
      <email>revival421@empal.com</email>
    </contact>
    <investigator>
      <last_name>Han-Suk Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 8, 2013</lastchanged_date>
  <firstreceived_date>April 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Han-Suk Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Pleuropneumonia</mesh_term>
    <mesh_term>Mycoplasma Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
